Découvrez ici la liste des différentes études cliniques en cours classées par centre.
Etudes sponsorisées interventionnelles en cours:
Etudes sponsorisées non interventionnelles en cours:
Etudes académiques non interventionnelles en cours:
| Etudes Onco en cours | |||
| 1st line | |||
| Acronyme | Studies | Cancer | PI |
| BO29554 study (B-FAST) | A phase II/III multicentre study evaluating the efficacy and safety of multiple targeted therapies as treatments for patients with advanced or metastatic non-small cell lung cancer (NSCLC) harbouring actionable somatic mutations detected in blood (B-Fast: blood-first assay screening trial) | NSCLC (ROS+) A venir: BRAF V600+ | P.C |
| ADRIATIC (D933QC00001) | Phase III, randomised, double-blind, placebo-controlled, multi-centre study assessing the efficacy and safety of durvalumab or durvalumab and tremelimumab in patients with LD-SCLC who have not progressed following definitive, platinum-based, concurrent chemoradiation therapy (CRT) | SCLC limités post-chimioradio | T.P |
| ANAM 17-21 | A phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to evaluate the efficacy and safety of Anamorelin HCl for the treatment of malignancy associated weight loss and anorexia in adult patients with advanced NSCLC | NSCLC cachexia | T.P |
| Zenith20 (Spectrum) (SPI-POZ-202) | Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20) (SPI-POZ-202) | NSCLC IV EGFR ou HER2 exon 20 inser/mut | T.P |
| CA209-73L | A Phase 3, Randomized, Open-Label Study to Compare Nivolumab Plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab Plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, Unresectable Locally Advanced Non-Small Cell Lung Cancer (LA NSCLC) | NSCLC IIIA/B/C | TP |
| 2nd line | |||
| ImmunoSABR | Phase II study examining the activity of L19-IL2 immunotherapy and stereotactic ablative radiotherapy in metastatic non-small cell lung cancer | NSCLC IV | X.G |
| AMG510 (20190009) | A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjects With Mutated KRAS p.G12C | NSCLC KRAS p.G12C | ThP |
| ≥ 3rd line | |||
| ImmunoSABR | Phase II study examining the activity of L19-IL2 immunotherapy and stereotactic ablative radiotherapy in metastatic non-small cell lung cancer | NSCLC IV | X.G |
| Autres | |||
| Acronyme | Studies | Cancer | PI |
| EORTC: E2-Radiate 1811 | E²-RADIatE: EORTC-ESTRO RADiotherapy InfrAstrucTure for Europe | Tous cancers oligométa traités par Rth | XG |
| PACIFIC R D4194R00005 | First real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy | NSCLC stage III with durvalumab post chimioradio | T.P |
| Immuno Poumon | Etude prospective des facteurs pronostics et prédictifs de l'immunothérapie dans le cancer du poumon | NSCLC | FAb |
| SPECTA | Screening Cancer Patients for Efficient Clinical Trial Access | NSCLC IV naïfs/ thymomes, mésothéliome IV naïfs | T.P |
| Pathologie-catégorie | Pathologie | Nom | Code | Eudract | Titre | Molecules | PhaseEtude |
| Poumons et Thorax | NSCLC/SCLC | 01151 | 01151 | Cardiovascular morbidities and lung cancer treatment: a prospective registry | Observationnelle | ||
| Poumons et Thorax | NSCLC | PDC-Lung-101 | PDC-Lung-101 | 2018-002382-19 | An open-label, dose escalation phase I/II study assessing the safety and immunogenicity of PDC*lung, therapeutic cancer vaccine, as single agent or in combination with a checkpoint inhibitor, in patients with Non-Small Cell Lung Cancer (NSCLC) | PDC*lung01 | Phase 1 Phase 2 |
| Poumons et Thorax | NSCLC | ANAM-17-21 | ANAM-17-21 | 2018-002927-40 | A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of anamorelin HCl for the treatment of malignancy associated weight loss and anorexia in adult patients with advanced non-small cell lung cancer (NSCLC) | Anamorelin HCL | Phase 3 |
| Poumons et Thorax | NSCLC | PACIFIC-4 | D9103C00001 | 2018-002572-41 | A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients With Unresected Stage I/II, Lymph-node Negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515) | Durvalumab | Phase 3 |
| Poumons et Thorax | NSCLC | CodeBreak 200 | 20190009 | 2019‐003582‐18 | A phase 3 multicenter, randomized, open label, active-controlled, study of AMG 510 versus docetaxel for the treatment of previously treated locally advanced and unresectable or metastatic NSCLC subjects with KRAS p.G12C mutation | AMG 510 | Phase 3 |
| Poumons et Thorax | NSCLC | EXCLAIM-2 (On hold - futility analysis) | TAK-788-3001 | 2019-001845-42 | Phase III clinical trial evaluating TAK-788 versus platinum-based chemotherapy (pemetrexed/cisplatin or pemetrexed/carboplatin) as first-line treatment for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations. | TAK-788 | Phase 3 |
| Poumons et Thorax | NSCLC | Skyscraper 03 | GO41854 | 2019-0044773-29 | A phase 3, open-label, randomized study of Atezolizumab and Tiragolumab compared with Durvalumab in patients with locally advanced, unresectable stage 3 non-small cell lung cancer who have not progressed after concurrent platinum-based chemoradiation. | Tiragolumab | Phase 3 |
| Poumons et Thorax | NSCLC | MARIPOSA | 73841937NSC3003 | 2020-000743-31 | A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Single Agent Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer – MARIPOSA | JNJ-61186372 Amivantamab | Phase 3 |
| Poumons et Thorax | NSCLC | SAPPHIRE | 516-005 | 2019-001043-41 | A randomized phase 3 study of Sitravatinib in combination with Nivolumab versus Docetaxel in patients with advanced non-squamous non-small cell lung cancer with disease progression on or after platinum-based chemotherapy and checkpoint inhibitor therapy. | Sitravatinib | Phase 3 |
| Poumons et Thorax | SCLC | MK7339-013 | MK7339-013 | 2019-003616-31 | A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib (MK-7339), Compared to Concurrent Chemoradiation Therapy Alone in Participants with Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) | Pembrolizumab (MK-3475) | Phase 3 |
| Toutes Tumeurs | Toutes tumeurs | Tumorbase | ONCOGHDC2017-01 | Prospective collection of biological samples for translational research on patients with tumoral or hematological diseases (TUMOR-base) | Prospective- Collection d'échantillons | ||
| Toutes Tumeurs | Toutes tumeurs | Precision 2 - Afatinib | 1200.264 | 2016-003411-34 | Precision 2: an open explorative phase II, open label study of afatinib in the treatment of advanced cancer carrying an EGFR, a HER2 or a HER3 mutation followed by the addition of paclitaxel to afatinib at disease progression. | Afatinib | Phase 2 |
| Toutes Tumeurs | Toutes tumeurs | DRIIV-1 / Phase Ib combo | OX2016-203-01 | 2017-000088-34 | Etude de Phase I/Ib d’escalade de dose en ouvert destinée à évaluer la tolérance,la pharmacocinétique et la pharmacodynamique d’AsiDNATM, un inhibiteur de réparation de l’ADN administré par voie intraveineuse en monothérapie et à évaluer la tolérance et l'efficacité d'AsiDNA administré en association avec Carboplatine avec ou sans Paclitaxel chez des patients atteints de tumeurs solides à un stade avancé. | AsiDNATM | Phase 1 Phase 1b |
| Toutes Tumeurs | Toutes tumeurs | Precision 2 – Olaparib | 1-2018 BSMO | 2018-002966-37 | Efficacy of Olaparib in advanced cancers occurring in patients with germline mutations or somatic tumor mutations in homologous recombination genes. SAUF SEIN, OVAIRE, PROSTATE, ATM gene | Olaparib | Phase 2 |
| Toutes Tumeurs | Toutes tumeurs | RAGNAR | 42756493CAN2002 | 2019-002113-19 | A Phase 2 Study of Erdafitinib in Subjects with Advanced Solid Tumors and FGFR Gene Alterations | Erdafitinib | Phase 2 Prospective- Collection d'échantillons |
| Toutes Tumeurs | Toutes tumeurs | Precision 1 | BSMO 2014-2 | The Belgian Molecular Profiling Program of Metastatic Cancer for Clinical Decision and Treatment Assignment “PRECISION 1” | Prospective- Collection d'échantillons | ||
| Toutes Tumeurs | Toutes tumeurs | GeNeo | BSMO 2020-01 | A study to examine the value of broad agnostic NGS panel testing versus reimbursed organ-directed NGS: a Belgian Precision study of the BSMO in collaboration with the Cancer Centre. | Prospective- Collection d'échantillons | ||
| Toutes Tumeurs | Toutes tumeurs | TAPISTRY | BO41932 | 2020-001847-16 | Phase II, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in rational, specified combinations in patients with unresectable, locally advanced or metastatic solid tumors determined to harbor specific oncogenic genomic alterations or who are TMB-high as identified by an next-generation-sequencing (NGS) assay | Phase 2 |
